USANA Health Sciences (NASDAQ: USNA) reported an insider stock sale and updated its near-term financial expectations in a pair of disclosures relevant to investors evaluating the company's outlook.
Insider transaction
- On March 3, 2026, Chief Information Officer Benedict Peter sold 4,553 shares of USANA common stock, as reported in a Form 4 filed with the Securities and Exchange Commission.
- The shares were sold at a weighted average price of $19.3848, producing gross proceeds of $88,258.
- Sale prices for the lots ranged between $19.29 and $19.415.
- Following the sale, the filing shows Benedict Peter directly holds 0 shares of USANA Health Sciences.
Company guidance and near-term outlook
USANA issued updated expectations for fiscal 2025 and preliminary guidance for 2026 in the same disclosure set. For fiscal 2025, the company now anticipates net sales of approximately $925 million, a modest increase from its prior guidance of $920 million. For fiscal 2026, USANA provided an initial revenue range of $925 million to $1 billion.
The company indicated the 2026 outlook incorporates an anticipated reduction in sales from its core nutritional business. Specifically, USANA expects core nutritional sales in 2026 to fall between $720 million and $765 million, compared with approximately $777 million forecast for 2025.
Partnership extension
Separately, USANA has agreed to extend its partnership with the Jamaica Bobsleigh and Skeleton Federation through 2032. The sponsorship, which began in early 2024, will continue to feature the USANA logo on the team’s bobsled, helmets, and racing suits.
These disclosures combine an executive stock sale with updated financial targets and a continuation of a sports sponsorship arrangement. The filing and company statements provide the specific transaction details, the revised sales figures for 2025, the initial 2026 revenue range and the projected decline in the nutritional segment, as well as the terms of the extended athletic partnership.